Potentiation of E-4031-induced torsade de pointes by HMR1556 or ATX-II is not predicted by action potential short-term variability or triangulation

British Journal of Pharmacology

Volumn 152, Issue 8, 2007, Pages 1215-1227

  Michael, G ^a   Dempster, J ^a   Kane, K A ^a   Coker, S J ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

Author keywords

ATX II; E 4031; HMR1556; I Kr; I Ks; I Na; K + channel blockers; Proarrhythmia; Repolarization reserve; Torsade de pointes

Indexed keywords

1 [2 (6 METHYL 2 PYRIDYL)ETHYL] 4 (4 METHYLSULFONYLAMINOBENZOYL)PIPERIDINE; ALPHA 1 ADRENERGIC RECEPTOR STIMULATING AGENT; N [3 HYDROXY 2,2 DIMETHYL 6 (4,4,4 TRIFLUOROBUTOXY)CHROMAN 4 YL] N METHYLMETHANESULFONAMIDE; PENTOBARBITAL; SEA ANEMONE TOXIN;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; HEART RATE; HEART VENTRICLE TACHYCARDIA; MALE; NONHUMAN; POTASSIUM CURRENT; PRIORITY JOURNAL; QT INTERVAL; QT PROLONGATION; RABBIT; SODIUM CURRENT; TORSADE DES POINTES; TRIANGULATION;

ACTION POTENTIALS; ANIMALS; CHROMANS; CNIDARIAN VENOMS; DELAYED RECTIFIER POTASSIUM CHANNELS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; ELECTROCARDIOGRAPHY; ELECTROPHYSIOLOGY; FORECASTING; LONG QT SYNDROME; MALE; PIPERIDINES; POTASSIUM CHANNELS, VOLTAGE-GATED; PYRIDINES; RABBITS; SODIUM CHANNELS; SULFONAMIDES; TORSADES DE POINTES;

EID: 36949022481     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707513     Document Type: Article

References (50)

1. Barrett TD, Hennan JK, Fischbach PS, O'Neill BP, Driscoll Jr EM, Lucchesi BR (2001). Tedisamil and dofetilide-induced torsades de pointes, rate and potassium dependence. Br J Pharmacol 132: 1493-1500.
2. Barrett TD, MacLeod BA, Walker MJ (1997). A model of myocardial ischemia for the simultaneous assessment of electrophysiological changes and arrhythmias in intact rabbits. J Pharmacol Toxicol Methods 37: 27-36.
3. Barrett TD, Walker MJ (1998). Glibenclamide does not prevent action potential shortening induced by ischemia in anesthetized rabbits but reduces ischemia-induced arrhythmias. J Mol Cell Cardiol 30: 999-1008.
4. Batey AJ, Coker SJ (2002). Proarrhythmic potential of halofantrine, terfenadine and clofilium in a modified in vivo model of torsade de pointes. Br J Pharmacol 135: 1003-1012.
5. Biliczki P, Virag L, Iost N, Papp JG, Varro A (2002). Interaction of different potassium channels in cardiac repolarization in dog ventricular preparations: role of repolarization reserve. Br J Pharmacol 137: 361-368.
6. Bril A, Gout B, Bonhomme M, Landais L, Faivre JF, Linee P et al. (1996). Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: experimental profile of BRL-32872. J Pharmacol Exp Ther 276: 637-646.
7. Carlsson L, Abrahamsson C, Andersson B, Duker G, Schiller-Linhardt G (1993). Proarrhythmic effects of the class III agent almokalant: importance of infusion rate, QT dispersion, and early after-depolarisations. Cardiovasc Res 27: 2186-2193.
8. Carlsson L, Almgren O, Duker G (1990). QTU-prolongation and torsades de pointes induced by putative class III antiarrhythmic agents in the rabbit: etiology and interventions. J Cardiovasc Pharmacol 16: 276-285.
9. Coats RA (1985). The effects of adrenoceptor agonists and antagonists on plasma potassium concentration in anaesthetized guineapigs, rabbits and rats. Br J Pharmacol 86: 827-836.
10. Detre E, Thomsen MB, Beekman JD, Petersen KU, Vos MA (2005). Decreasing the infusion rate reduces the proarrhythmic risk of NS-7: confirming the relevance of short-term variability of repolarisation in predicting drug-induced torsades de pointes. Br J Pharmacol 145: 397-404.
11. Eckardt L, Haverkamp W, Mertens H, Johna R, Clague JR, Borggrefe M et al. (1998). Drug-related torsades de pointes in the isolated rabbit heart: comparison of clofilium, d,l-sotalol, and erythromycin. J Cardiovasc Pharmacol 32: 425-434.
12. Farkas A, Batey AJ, Coker SJ (2004). How to measure electrocardiographic QT interval in the anaesthetized rabbit. J Pharmacol Toxicol Methods 50: 175-185.
13. Farkas A, Coker SJ (2002). Limited induction of torsade de pointes by terikalant and erythromycin in an in vivo model. Eur J Pharmacol 449: 143-153.
14. + channels. Eur J Pharmacol 472: 189-196.
15. Gil AG, Silvan G, Illera M, Illera JC (2004). The effects of anesthesia on the clinical chemistry of New Zealand White rabbits. Contemp Top Lab Anim Sci 43: 25-29.
16. Ks channels by HMR 1556. Naunyn Schmiedebergs Arch Pharmacol 362: 480-488.
17. Hanck DA, Sheets MF (2007). Site-3 toxins and cardiac sodium channels. Toxicon 49: 181-193.
18. Haverkamp W, Breithardt G, Camm AJ, Janse MJ, Rosen MR, Antzelevitch C et al. (2000). The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 47: 219-233.
19. Hondeghem LM, Carlsson L, Duker G (2001). Instability and triangulation of the action potential predict serious proarrhythmia, but action potential duration prolongation is antiarrhythmic. Circulation 103: 2004-2013.
20. Hondeghem LM, Lu HR, van Rossem K, De Clerck F (2003). Detection of proarrhythmia in the female rabbit heart: blinded validation. J Cardiovasc Electrophysiol 14: 287-294.
21. Ks in human ventricular muscle. Circulation 112: 1392-1399.
22. KAch class Ic drugs and beta blockers in pigs. Med Sci Monit 10: BR221-BR228.
23. Ks) fails to lengthen rabbit ventricular muscle QT(c) and action potential duration. Br J Pharmacol 132: 101-110.
24. Ks increases short-term QT interval variability and provokes torsades de pointes. Br J Pharmacol 151: 941-951.
25. Lightbown ID, Lambert JP, Edwards G, Coker SJ (2001). Potentiation of halofantrine-induced QTc prolongation by mefloquine: correlation with blood concentrations of halofantrine. Br J Pharmacol 132: 197-204.
26. Liu T, Brown BS, Wu Y, Antzelevitch C, Kowey PR, Yan G-X (2006). Blinded validation of the isolated arterially perfused rabbit ventricular wedge in preclinical assessment of drug-induced proarrhythmias. Heart Rhythm 3: 948-956.
27. Lu HR, Vlaminckx E, Van De Water A, Gallacher DJ (2006). Calmodulin antagonist W-7 prevents sparfloxacin-induced early afterdepolarizations (EADs) in isolated rabbit Purkinje fibers: importance of beat-to-beat instability of the repolarization. J Cardiovasc Electrophysiol 17: 415-422.
28. Michael G, Kane KA, Coker SJ (2006). Repolarisation reserve and the development of torsade de pointes in models of long QT syndromes 1 and 2. J Mol Cell Cardiol 40: 985.
29. Michael G, Kane KA, Coker SJ (2007). The effect of ATX-II on torsade de pointes induced by E-4031 in vivo. J Mol Cell Cardiol 42: S7-S8.
30. Milberg P, Reinsch N, Wasmer K, Monnig G, Stypmann J, Osada N et al. (2005). Transmural dispersion of repolarization as a key factor of arrhythmogenicity in a novel intact heart model of LQT3. Cardiovasc Res 65: 397-404.
31. + channel inactivation prolongs QT interval and aggravates adrenaline-induced arrhythmias. Jpn J Pharmacol 86: 114-119.
32. Nakashima H, Gerlach U, Schmidt D, Nattel S (2004). In vivo electrophysiological effects of a selective slow delayed-rectifier potassium channel blocker in anesthetized dogs: potential insights into class III actions. Cardiovasc Res 61: 705-714.
33. Orosz S, Farkas A, Makra P, Csik N, Lepran I, Rudas L et al. (2007). Repolarization-related ECG parameters do not predict the proarrhythmic activity of dofetilide. J Mol Cell Cardiol 42: S6.
34. 2+ overload. Pharmacol Res 39: 167-174.
35. Roden DM (1998). Taking the 'idio' out of 'idiosyncratic': predicting torsades de pointes. Pacing Clin Electrophysiol 21: 1029-1034.
36. + current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol 96: 195-215.
37. Shimizu W, Antzelevitch C (1997). Sodium channel block with mexiletine is effective in reducing dispersion of repolarization and preventing torsade des pointes in LQT2 and LQT3 models of the long-QT syndrome. Circulation 96: 2038-2047.
38. Ks by HMR 1556 increases the reverse rate-dependence of refractoriness prolongation by dofetilide in isolated rabbit ventricles. Br J Pharmacol 148: 255-263.
39. Na in guinea pig ventricular myocytes. J Cardiovasc Pharmacol 44: 192-199.
40. Thomas GP, Gerlach U, Antzelevitch C (2003). HMR 1556, a potent and selective blocker of slowly activating delayed rectifier potassium current. J Cardiovasc Pharmacol 41: 140-147.
41. Thomsen MB (2007). Double pharmacological challenge on repolarization opens new avenues for drug safety research. Br J Pharmacol 151: 909-911.
42. Thomsen MB, Oros A, Schoenmakers M, van Opstal JM, Maas JN, Beekman JDM et al. (2007). Proarrhythmic electrical remodelling is associated with increased beat-to-beat variability of repolarisation. Cardiovasc Res 73: 521-530.
43. Thomsen MB, Verduyn SC, Stengl M, Beekman JDM, de Pater G, van Opstal J et al. (2004). Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 110: 2453-2459.
44. Thomsen MB, Volders PGA, Beekman JDM, Matz J, Vos MA (2006). Beat-to-beat variability of repolarization determines proarrhythmic outcome in dogs susceptible to drug-induced torsades de pointes. J Am Coll Cardiol 48: 1268-1276.
45. Ks in dog ventricular muscle and Purkinje fibre repolarization. J Physiol (London) 523: 67-81.
46. Ks to canine ventricular repolarization: key role for β-adrenergic receptor stimulation. Circulation 107: 2753-2760.
47. Walker MJA, Curtis MJ, Hearse DJ, Campbell RWF, Janse MJ, Yellon DM et al. (1988). The Lambeth Conventions - guidelines for the study of arrhythmias in ischemia, infarction, and reperfusion. Cardiovasc Res 22: 447-455.
48. Wu L, Shryock JC, Song Y, Belardinelli L (2006). An increase in late sodium current potentiates the proarrhythmic activities of low-risk QT-prolonging drugs in female rabbit hearts. J Pharmacol Exp Ther 316: 718-726.
49. Wu L, Shryock JC, Song Y, Li Y, Antzelevitch C, Belardinelli L (2004). Antiarrhythmic effects of ranolazine in a guinea pig in vitro model of long-QT syndrome. J Pharmacol Exp Ther 310: 599-605.
50. Yang T, Roden DM (1996). Extracellular potassium modulation of drug block of Ikr. Implications for torsade de pointes and reverse use-dependence. Circulation 93: 407-411.